Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBlue KC formulary coverage & Prior Auth Policy Upd…
    Ask Trek AI about this page
    CurrentBlue KCPolicy N/A

    Prescription drug formulary and benefit rules

    Customize your policy alerts

    Sign up for all Blue KC policy alerts

    Know when Blue KC releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs coverage, tiering, prior authorization, step therapy, and quantity limits for prescription drugs and related supplies for Blue KC members as reflected in the drug benefit schedule and formulary lists. Affects Blue KC members, prescribing providers, and pharmacies.

    Policy Summary
    PayerBlue KC
    PolicyPrescription drug formulary and benefit rules
    Policy CodePolicy N/A
    Change TypeNo material change indicated
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization when required by the Plan before filling prescriptions for drugs marked PA.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    PAPrior Authorization (PA)
    STStep Therapy (ST)
    QLQuantity Limits (QL)
    $0Copay waiver possible
    90-day90-day supply

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    10/8/2024Document updated

    Coverage Criteria & Formulary Stance

    High-level coverage stance

    Coverage and member cost sharing are determined by the member certificate benefit schedule and formulary; certain items have special coverage rules or exception processes.

    Please see the benefit schedule in your member certificate for member cost sharing associated with Generic and Brand (Preferred and Non Preferred) drugs.

    Special provisions

    • Tier Exception Requests: If for medical reasons a contraceptive or HIV PrEP medication is not included on the Preventive Service list, a member may request an exception to waive otherwise applicable cost sharing; the member's doctor must complete and submit the request online at bluekc.com.
    • Syringe and Needle Coverage: Syringes and needles are covered by prescription only, and only for members taking medications requiring injection; Techlite/Arkray supplies are covered at $0 and other syringe/needle products are covered at a non-preferred brand copay.

    Refer to the formulary listing and detailed policy sections for per-product utilization controls (PA, QL, PV, ST) and exact coverage rules.

    Tier Exception Requests for Contraceptives & HIV PrEP

    Tier exceptions are available for select preventive medications.

    Tier Exception Requests for Contraceptives & HIV Pre-Exposure Prophylaxis (PrEP): If, for medical reasons, a contraceptive or HIV PrEP medication is not included on the Preventive Service list(s), the member may request an exception to waive otherwise applicable cost sharing.
    Operational step: The member’s prescribing physician must complete and submit the exception request online at bluekc.com.

    Syringe and Needle Coverage

    Coverage for syringes and needles is limited and subject to prescription requirements.

    Syringes and needles are covered by prescription only and only for members taking medications requiring injection.
    Techlite/Arkray supplies are covered at $0; all other syringe/needle products are covered at a non-preferred brand copay.

    excerpt coverage annotations

    Selected coverage-related annotations visible in this excerpt (partial):

    Quantity limits (examples)

    • Morphine sulfate oral tablet 30 mg — Limits Required = QL (3 EA per day).
    • Buprenorphine sublingual formulations — Limits Required examples include QL (12 EA per 1 day) and QL (3 EA per 1 day).
    • Linezolid oral tablet — Limits Required = QL (28 EA per 30 days).
    • Memantine HCl ER — Limits Required = QL (1 EA per 1 day).

    Prior authorization (examples)

    • XIFAXAN ORAL TABLET 550 MG — marked as PA.

    Sample coverage nodes from listed controls

    Listings show drug-specific utilization controls; where PA is indicated, prior authorization is required before coverage.

    Memantine HCl ER — QL (1 EA per 1 day) (example of a per-product quantity limit shown in the TOC).
    Migraine CGRP agents (e.g., AIMOVIG, AJOVY) — Limits Required entries indicate PA; QL values are shown for specific formulations (examples in listing).
    Many Molecular Target Inhibitors and specialty oral oncology agents (e.g., ALECENSA, BOSULIF, CABOMETYX) are listed with Limits Required = PA indicating prior authorization is required for coverage.

    Summary of controls in TOC

    Formulary control indicators shown in the Table of Contents (indicative only; refer to the detailed policy sections for complete criteria):

    Prior Authorization (PA): many entries in the TOC include 'Limits Required = PA' indicating prior authorization is required for coverage of those drugs.
    Quantity Limits (QL): some TOC entries include 'QL' with explicit unit/time specifications (examples include per day or per period limits shown next to drug names).
    Drug categorization: the TOC enumerates therapeutic classes and individual agents (e.g., Molecular Target Inhibitors, Anti-hepatitis C agents) but specific coverage criteria are determined by the Limits Required flags and detailed section rules.

    Utilization control summary from table

    Utilization controls shown in the list (examples):

    Controls shown

    • PA: Prior authorization required for listed drugs (examples in TOC include maraviroc and certain CGM devices marked PA).
    • QL: Quantity limits specified with explicit limits and timeframes (examples include 'QL (1 EA per day)', 'QL (40 EA per 365 days)', 'QL (360 ML per 365 days)').
    • ST: Step therapy required for select agents (e.g., JANUMET, JANUMET XR, JANUVIA, JENTADUETO and related entries indicate 'ST').

    These are illustrative examples from the TOC; consult each detailed product section for the full criteria and documentation required for authorization or exception requests.

    Formulary controls (index)

    Formulary control indicators present in this excerpt (index entries and TOC fragments):

    TOC fragments list products with Limits Required annotations; presence of PA, QL, PV, or ST in the Limits Required field indicates managed coverage or limits applied to the item.
    Examples shown in TOC fragments include PA and QL annotations for specialty injectables and biologics (e.g., REPATHA entries show PA; QL values are provided for certain presentations).

    Coverage stance from table entries

    Table entries indicate coverage status via utilization controls. Items shown with 'PA' or 'QL' imply coverage is subject to authorization or quantity limits.

    Fibromyalgia agents and certain biologics in the TOC show combinations of PA and QL (examples: pregabalin and DUPIXENT entries include PA and/or QL annotations).
    TOC entries that list 'PA; QL (...)' indicate both prior authorization and specified quantity limits apply to that product presentation.

    Formulary limits and flags (excerpt)

    Formulary entries and their associated limits/flags (excerpt):

    ANY of the following

    • GATTEX — Limits Required = PA (example of PA flag applied to gastrointestinal agent).
    • LINZESS — Limits Required = ST; QL (1 EA per 1 day) (example of step therapy with quantity limit).
    • Rabeprazole sodium oral tablet delayed — Limits Required = QL (1 EA per day) (example of QL for proton pump inhibitor).

    These nodes are illustrative product-level entries extracted from the TOC; full coverage criteria and any clinical documentation requirements are defined in the detailed policy sections.

    Coverage controls in table of contents

    Listing of drugs with associated coverage-control flags; presence of PA/PV/QL implies managed coverage requiring authorization or limits.

    Many reproductive health products (e.g., MENOPUR, NEXPLANON, MIRENA, SKYLA) are listed with PV in the Limits Required field indicating a verification or coverage designation.
    Selected growth-hormone and fertility products (e.g., NUTROPIN AQ, OMNITROPE) show PA or PV designations in the TOC indicating additional administrative controls apply.

    Administrative controls (PA/PV/QL)

    Administrative coverage controls shown in the Table of Contents entries

    ANY of the following

    • Prior Authorization (PA): noted for many products (examples: LUPRON DEPOT entries, octreotide acetate, SIGNIFOR) indicating PA is required before coverage is approved.
    • Quantity Limits (QL): specific QL values appear alongside product entries (examples: SIGNIFOR = QL (2 ML per 1 day); OTEZLA = QL (2 EA per 1 day) and therapy pack limits).
    • Prior Validation (PV): certain vaccines and contraceptives are marked PV (e.g., BEYFORTUS, ACTHIB, FLUARIX) indicating a prospective validation or verification workflow rather than standard PA.

    Presence of these flags in the TOC signifies administrative controls; consult product-specific criteria for clinical or documentation requirements for authorization or validation.

    coverage_flags_and_limit_rules

    This section is a table-of-contents-style listing of drugs/devices with assigned categories and limit/authorization flags; specific coverage criteria are indicated by those flags and per-product QL values.

    Items labeled PA require prior authorization per payer policy; TOC examples include XIAFLEX, KALYDECO, PULMOZYME.
    Items labeled QL have specified quantity limits (daily, per fill, per period); the TOC lists the numeric QL value adjacent to the product name when applicable.
    Items labeled PV indicate a verification or coverage designation applied to certain contraceptives and barriers (e.g., condoms, diaphragms, PARAGARD).

    Drug Category codes categorize products but coverage status depends on Limits Required flags and underlying policy criteria.

    Utilization controls (partial)

    Utilization controls noted for specific drugs in the index (partial):

    ANY of the following

    • Cystic fibrosis agents: KALYDECO — Limits Required = PA; ORKAMBI — Limits Required = PA; QL values shown for ORKAMBI formulations (e.g., QL (2 EA per 1 day) and QL (112 EA per 28 days)).
    • Pulmonary antihypertensives (e.g., ADEMPAS, ambrisentan, bosentan) — listed with PA and product-specific QL values (examples shown in TOC).
    • Biologics and specialty agents (e.g., NUCALA) — Limits Required = PA and may include QL (per day) specifications for particular presentations.

    These entries are partial TOC extracts; review the full product policy sections for clinical criteria, dosing and documentation needed for authorization or dispensing within QL limits.

    Table of Contents — no coverage criteria in excerpt

    No coverage criteria or decision nodes are present in this excerpt. Refer to the corresponding detailed sections (pages/indices referenced in the full document) for coverage rules.

    This excerpt is a Table of Contents listing drug and product names with page/index references; it does not include the detailed clinical coverage criteria. For coverage decisions, consult the detailed product-specific sections referenced in the full formulary/policy document.

    Index entries

    Table of contents entries (informational):

    The TOC continues across multiple pages and lists additional drug/product entries and index numbers; entries themselves are informational in this excerpt and do not convey the full coverage criteria.

    Accessibility and Language Services

    Member rights and assistance information included in the document context.

    Blue Cross and Blue Shield of Kansas (Blue KC) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex; the plan provides free aids and language services including qualified interpreters and written materials in other formats.
    Operational contact: To speak with an interpreter, members may call the Blue KC interpreter services phone number listed in the policy materials (example provided in the TOC excerpt).

    Formulary Codes, Flags, and Quantity Limits

    Formulary abbreviations / status codesmixed
    PVAvailable at $0 if Health Care Reform copay waiver is approved
    PAPrior Authorization required
    STStep Therapy required
    QLQuantity Limit applies
    Formulary abbreviations / status codes (source index)mixed
    No codes listed
    Utilization flags appearing in excerptmixed
    QLQuantity Limit (examples: QL (3 EA per day), QL (12 EA per 1 day), QL (2 EA per 1 day))
    PAPrior Authorization required (examples: XIFAXAN 550 mg marked PA; EPIDIOLEX marked PA)
    PVProgram/verification flag (appears with smoking cessation products)
    STStep therapy requirement (appears for NICOTROL, NICOTROL NS)
    Utilization control flags used in tablemixed
    QAQuantity limits denoted as QL (example formats shown: 'QL (1 EA per 1 day)', 'QL (84 EA per 180 days)')
    PAPrior authorization required as indicated by 'Limitsl Required = PA'
    STStep therapy required as indicated by 'Limitsl Required = ST'
    Drugs listed without CPT/HCPCS/NDC codes in this excerptmixed
    Drug names and strengths as listed in the Table of Contents; no billing codes provided in this excerpt
    Examples (molecular target inhibitors)mixed
    ALECENSAListed in TOC with Limits Required = PA (no CPT/HCPCS/NDC provided in excerpt)
    BOSULIFListed in TOC with Limits Required = PA (no CPT/HCPCS/NDC provided in excerpt)
    CABOMETYXListed in TOC with Limits Required = PA (no CPT/HCPCS/NDC provided in excerpt)
    Utilization control flags appearing in listmixed
    PAPrior Authorization required (as noted in Limitsl Required field)
    QLQuantity Limit (example: 'QL (1 EA per day)' or 'QL (40 EA per 365 days)')
    STStep Therapy required (noted as 'ST' in Limitsl Required)
    Formulary entries (no CPT/HCPCS/ICD codes)mixed
    No billing or procedure codes provided in this excerpt; entries are formulary drug names, categories, and utilization controls.
    Drug category classificationmixed
    1-4Drug Category levels shown in the table (e.g., 1, 2, 3, 4) used to classify drugs
    Examples (biologics limits)mixed
    PA; QLExamples: SKYRIZI, SPEVIGO, STELARA entries show PA; QL values in TOC (no billing codes in excerpt)
    Thyroid product formulationsmixed
    Multiple strengths and formulations of levothyroxine and related thyroid products are listed (strengths enumerated); no procedure codes provided in excerpt
    Examplesmixed
    levo-t / levothyroxine / unithroid / levoxylVarious oral tablet strengths enumerated in TOC (no CPT/HCPCS/NDC codes in excerpt)
    Quantity limit annotationsmixed
    QL examplesQuantity limits annotated in TOC (examples: QL (55 EA per 365 days) for OTEZLA therapy pack; QL (1 EA per 1 day) for RINVOQ)
    Vaccine PV flagsmixed
    PVPV noted for many vaccines in TOC (e.g., FLUARIX, FLUCELVAX)
    limit_and_auth_codesmixed
    QLQuantity Limit — value specified per product (e.g., QL (0.1 ML per 1 day), QL (18 ML per 1 day))
    PAPrior Authorization required for some products (e.g., XIAFLEX, PULMOZYME, KALYDECO)
    PVCoverage/verification flag used on several items (e.g., condoms, diaphragms, PARAGARD)
    STStep therapy flag present for select products (e.g., zileuton er = ST)
    Examples of quantity limits from listingmixed
    QL (2 EA per 1 day)Quantity limit for ORKAMBI oral packet 75-94 mg
    QL (112 EA per 28 (days)Quantity limit for ORKAMBI oral tablet
    QL (3 EA per 1 day)Quantity limit for ADEMPAS
    Formulary entries (no codes)mixed
    This section is a listing of drug names and product variants; no specific billing or diagnosis codes provided in these chunks.
    Table of contents entriesmixed
    No billing or procedure codes present in these chunks; content is a TOC of drug/product names and page/index references
    Quantity limits examples — assorted
    Example daily QLQL (2 EA per 1 day)
    Example per-fill QL (volume)QL (2.5 ML per 1 fill)
    Higher daily QLQL (40 EA per 1 day)
    examples of quantity limits — sample patterns
    3 EA per day example

    Provider Requirements, Prior Authorization & Step Therapy

    Prior Authorization

    Provider Requirements — Prior Authorization, Step Therapy & Quantity Limits

    PA = Prior Authorization: The Plan requires prior authorization for many listed drugs, devices and supplies. Lack of prior authorization may result in noncoverage. PV = Prior Validation/Verification: Items marked PV require coverage verification (examples include certain vaccines, contraceptives, and OTC devices). ST = Step Therapy: The Plan may require trial of specified first‑line agents before covering alternatives. QL = Quantity Limit: The Plan limits the amount and/or frequency of coverage for specified products.

    • PA examples (partial): XIFAXAN; many Molecular Target Inhibitors (ALECENSA, BOSULIF, CABOMETYX, CAPRELSA, COMETRIQ, COTELLIC, dasatinib, ERIVEDGE, etc.); specialty biologics (REPATHA, DUPIXENT, NUCALA, NUCALA presentations, ILARIS, ACTEMRA, BENLYSTA, GAMMAGARD, HIZENTRA, etc.); selected antiemetics and antiinfectives; select pulmonary antihypertensives (ADEMPAS, TYVASO, VENTAVIS, sildenafil/tadalafil for PAH); cystic fibrosis agents (KALYDECO, ORKAMBI); selected oncology and orphan agents (XIAFLEX, ZOKINVY).
    • PV examples (partial): nicotine replacement products and many contraceptive/barrier items (PARAGARD = PV; WIDE‑SEAL DIAPHRAGMS = PV); BEYFORTUS presentations (PV; QL); various laxative OTC items flagged PV with annual fill limits.
    • ST examples (partial): Certain dermatologic and specialty topical products and some neurology/other agents are noted with ST flags in the Table of Contents.
    • QL examples: A wide range of drugs and devices include specific quantity limits such as: aprepitant capsules (QL per 30 days), ondansetron oral solution QL (4 mL/day), granisetron QL, terbinatine oral QL (84 EA per 180 days), CONTOUR/TEST STRIPS QL (10 EA per day), many CGRP migraine therapies with per‑day/per‑dose QLs, NUCALA QL (0.11 mL per day or other presentations), REPATHA QL (0.11–0.13 mL per day), SIGNIFOR QL (2 mL per day), BEYFORTUS QL (per 300 days), ADEMPAS QL (3 EA per day), TYVASO/VENTAVIS QLs, and numerous others.

    Key Definitions & Formulary Flags

    Key formulary definitions (PA / ST / QL / PV)
    Prior Authorization (PA)The Plan requires you or your physician to get prior authorization for certain drugs; if you don't get approval, the plan may not cover the drug.
    Step Therapy (ST)The Plan may require trying specified first-line drugs before covering alternative drugs for the same condition.
    Quantity Limit (QL)For certain drugs, the Plan limits the amount of the drug that we will cover (numerical dispensing limits shown next to drugs).
    PVPV*, noted in list, indicates availability at $0 if Health Care Reform copay waiver is approved (or denotes prior verification/plan verification in Limits/Required).
    Policy Summary
    PayerBlue KC
    PolicyPrescription drug formulary and benefit rules
    Policy CodePolicy N/A
    Change TypeNo material change indicated
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization when required by the Plan before filling prescriptions for drugs marked PA.
    SourceLink
    On This Page
    Coverage Criteria & Formulary StanceFormulary Codes, Flags, and Quantity LimitsProvider Requirements, Prior Authorization & Step TherapyKey Definitions & Formulary Flags
  1. EPIDIOLEX — Limits Required = PA.
  2. Step therapy / PV flags

    • NICOTROL / NICOTROL NS — Limits Required = ST (step therapy) indicated in listing.
    • Certain smoking-cessation and contraceptive products — Limits Required = PV (verification/coverage flag) and may include QL annotations (e.g., nicotine products with QL (180 EA per 365 days)).
    QL (3 EA per day)
    12 EA per 1 day exampleQL (12 EA per 1 day)
    180 EA per 365 days exampleQL (180 EA per 365 days)
    28 EA per 30 days exampleQL (28 EA per 30 days)
    terbinafine limit
    Terbinafine oral QLQL (84 EA per 180 days)
    memantine ER daily limit
    Memantine ER daily QLQL (1 EA per 1 day)
    Example quantity limit format
    Quantity limit formatQL (n EA per m day)
    InterpretationSpecifies maximum units (EA) allowed within the stated time period (day/365 days/etc.)
    PlacementQL values appear in parentheses next to product entries in the Table of Contents
    Examples of specified quantity limits
    1 EA per dayQL (1 EA per 1 day)
    40 EA per 365 daysQL (40 EA per 365 days)
    360 ML per 365 daysQL (360 ML per 365 days)
    60 EA per 365 daysQL (60 EA per 365 days)
    Quantity limits examples — multiple entries
    1 EA per 1 dayQL (1 EA per 1 day)
    0.11 ML per 1 dayQL (0.11 ML per 1 day)
    16 EA per 1 dayQL (16 EA per 1 day)
    Quantity limits examples — additional values
    0.29 ML per 1 dayQL (0.29 ML per 1 day)
    3 GM per 1 dayQL (3 GM per 1 day)
    24 EA per 365 daysQL (24 EA per 365 days)
    Example quantity limits — varied examples including large annual volumes
    1 EA per 1 dayQL (1 EA per 1 day)
    2 EA per dayQL (2 EA per day)
    8000 ML per 365 days (example large annual volume)QL (8000 ML per 365 days)
    Quantity limits examples — small-unit examples
    0.6 ML per 1 dayQL (0.6 ML per 1 day)
    0.06 ML per 1 dayQL (0.06 ML per 1 day)
    0.15 EA per 1 dayQL (0.15 EA per 1 day)
    Sample QL thresholds — assorted
    0.6 ML per 1 dayQL (0.6 ML per 1 day)
    2 ML per 300 daysQL (2 ML per 300 days)
    55 EA per 365 daysQL (55 EA per 365 days)
    examples_of_quantity_limits — per-product examples
    28 EA per 1 fillQL (28 EA per 1 fill)
    0.72 ML per 1 dayQL (0.72 ML per 1 day)
    18 ML per 1 dayQL (18 ML per 1 day)
    112 EA per 28 daysQL (112 EA per 28 days)
    QL examples — daily and 28-day limits for select drugs
    Daily QL example (ml)QL (1 ML per 1 day)
    28-day QL exampleQL (24 EA per 365 days)
    Daily EA QL exampleQL (3 EA per day)
  3. CGRP migraine therapies: AIMOVIG, AJOVY, EMGALITY, NURTEC and others appear with PA and/or QL flags (examples: AIMOVIG PA; QL per day, AJOVY PA; QL, NURTEC PA; QL).
  4. Durable medical devices and continuous glucose monitoring (CGM): Multiple device entries are marked PA under Limits/Required — examples include DEXCOM G6/G7 receiver, sensor and transmitter (PA), GUARDIAN sensors/transmitters (PA), and select insulin pump/CGM pods and kits. Prior authorization is required for many DME/CGM components.
  5. Table of Contents indicators: The Table of Contents repeatedly annotates Limit requirements for many entries (PA, PV, ST, QL). Providers should consult the formulary TOC for specific flags per product and formulation.
  6. Specific product examples (partial): • Ondansetron oral solution QL (4 mL/day). • Aprepitant oral capsule QL (1–4 EA per 30 days depending on strength). • Metyrosine: PA; QL (16 EA per day). • VYNDAMAX: PA; QL (1 EA per day). • REPATHA and REPATHA PUSHTRONEX: PA; QL (0.11–0.13 mL per day). • DUPIXENT, SKYRIZI: PA; QL (per‑day mL limits). • KALYDECO, ORKAMBI: PA; ORKAMBI QL examples (2 EA per day; 112 EA per 28 days listed).
  7. Pulmonary antihypertensives: Agents such as ADEMPAS, TYVASO (multiple kit/refill designations), VENTAVIS, TRACLEER, treprostinil, sildenafil/tadalafil for PAH are annotated PA and often include explicit QLs (EA or mL per day).
  8. Biologic examples: NUCALA products, ACTEMRA, BENLYSTA, ILARIS and multiple immunoglobulin products (GAMMAGARD, GAMUNEX‑C, HIZENTRA) are designated PA; many include QLs (mL or EA per day or per period).
  9. Contraceptives and verification flags: Several contraceptive devices and barrier products (PARAGARD, WIDE‑SEAL DIAPHRAGMS, IUDs like MIRENA) are marked PV indicating coverage verification rather than PA in some cases.
  10. Coverage action for providers: Prior authorization or verification must be requested before dispensing/servicing PA/PV flagged items. For products with QL or ST flags, submit clinical justification and documentation of prior trials or dosing history as required by the Plan.
  11. Accessibility & Language Services: Blue KC provides non‑discrimination and language access services, including qualified interpreters and written materials in alternative formats. For language assistance call 1‑844‑395‑7126.
  12. Note

    Table of Contents — Limits/Required Flags

    The Table of Contents includes many entries annotated with Limits/Required flags (PA, PV, ST, QL). Use the TOC as a quick reference to identify which product formulations and devices require prior authorization, verification, step therapy, or are subject to quantity limits.

    • TOC examples: • Molecular Target Inhibitors section lists many drugs with Limits/Required = PA (ALECENSA, BOSULIF, CABOMETYX, CAPRELSA, COMETRIQ, COTELLIC, dasatinib, ERIVEDGE, etc.). • CGRP migraine therapy entries show PA and QL flags for AIMOVIG, AJOVY, EMGALITY and others. • Device/CGM entries (DEXCOM G6/G7, GUARDIAN sensors/transmitters) are marked PA in the TOC. • Multiple biologics, immunoglobulins and specialty injectables show PA; QL annotations in the TOC (ACTEMRA, ILARIS, NUCALA, GAMMAGARD, etc.).
    Documentation Required

    Provider Submission Requirements

    When submitting prior authorization requests include: drug/device name, NDC or product identifier, dosing regimen, duration, relevant prior therapy trials (for ST), and supporting clinical documentation. For items marked PV, include coverage verification details per payer instructions.

    • If a product is PA: do not dispense until authorization is approved to avoid noncoverage. • For ST: document failure, intolerance, or contraindication to required first‑line agents. • For QL: indicate medical necessity for quantities beyond standard limits when applicable. • For DME/CGM: include device order, device-specific model/part numbers, and clinical justification.